Canagliflozin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 6: Line 6:
Canagliflozin also inhibits renal SGLT1, contributing to about 10% of daily urinary glucose excretion.<ref name="a35">PMID:32064793</ref><ref name="a36">PMID:34232488</ref>
Canagliflozin also inhibits renal SGLT1, contributing to about 10% of daily urinary glucose excretion.<ref name="a35">PMID:32064793</ref><ref name="a36">PMID:34232488</ref>
-
This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin.[37]
+
This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin.<ref name="a37">Klement A (20 January 2014). "Tubuläre Senkung des Blutzuckers bei Diabetes mellitus: Invokana". Österreichische Apothekerzeitung (in German) (2/2014): 20f.</ref>
[[8hdh]].
[[8hdh]].

Revision as of 08:27, 24 January 2024

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. "Canagliflozin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.
  2. "Integrity - Clarivate"
  3. Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. PMID:32064793 doi:10.1002/psp4.12498
  4. Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? Drugs. 2021 Aug;81(12):1365-1371. PMID:34232488 doi:10.1007/s40265-021-01559-1
  5. Klement A (20 January 2014). "Tubuläre Senkung des Blutzuckers bei Diabetes mellitus: Invokana". Österreichische Apothekerzeitung (in German) (2/2014): 20f.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools